Latest revenue
$0
as of 2026-03-31
Latest net income
$-17.0M
as of 2026-03-31
Net margin
—
as of 2026-03-31
Community sentiment
Where do you think OVID is heading?
Keep private notes on OVID — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
OVID vs S&P 500 · rebased to 100
Market data
Price feed temporarily unavailable for OVID.
What this company does
Item 1. BUSINESS Overview Ovid is a biopharmaceutical company that is dedicated to developing small molecule medicines for brain disorders with significant unmet need. These potential medicines targeting the central nervous system (“CNS”) are designed to potentially halt the course of brain disease by quelling neuronal hyperexcitation and alleviating the most impactful patient symptoms. We seek to address fundamental biological targets in the brain that are implicated in neuronal hyperexcitability, such as neurotransmitters and dysregulated ion channels. By mitigating excessive neuronal hyperexcitation with differentiated medicines, we believe we can unlock substantial scientific,…
AI summary unavailable — showing raw filing excerpt
Generated from OVID's filing dated 2026-03-18
Key risks
Item 1A. Risk Factors An investment in our securities involves a high degree of risk. You should carefully consider the following information about these risks, together with the other information appearing elsewhere in this Annual Report on Form 10-K, including our audited consolidated financial statements and related notes hereto, before deciding to invest in our common stock. The occurrence of any of the following risks could have a material adverse effect on our business, financial condition, results of operations and future growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may…
AI summary unavailable — showing raw filing excerpt
Generated from OVID's filing dated 2026-03-18
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 10, 2026.